Emerging treatments in oncology: Focus on tyrosine kinase (erbB) receptor inhibitors

Journal of the American Pharmacists Association

Volumn 44, Issue 1, 2004, Pages 52-58

  Hamid, Oday ^a  

^a PFIZER INC   (United States)

Author keywords

Cancer treatments; Gefitinib; New drugs; Oncology; Trastuzumab; Tyrosine kinase receptor inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEW DRUG; PROTEIN TYROSINE KINASE;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 1442283808     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434504322713237     Document Type: Review

References (59)

1. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol.1995;19:183-232.
2. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000;77:7725-9.
3. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159-67.
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-25.
5. Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell. 2000;103:13-5.
6. Hernandez-Sotomayor SMT, Carpenter G. Epidermal growth factor receptor: elements of intracellular communication. J Membr Biol. 1992;128:81-9.
7. Kelloff GJ, Fay JR, Steele VE, et al. Epidermal growth factor receptor kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1996;5:657-66.
8. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther. 1999;82:207-18.
9. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241-50.
10. Fedi P, Kimmelman A, Aaronson SA. Cancer medicine. In: Kufe D, Pollock R, Weichselbaum R, et al. Growth factor signal transduction in cancer. 5th ed. Hamilton, Ontario: BC Decker; 2000:33-55.
11. Shelly M, Pinkas-Kramarski R, Guarino BC, et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem. 1998;273:10496-505.
12. Wen D, Suggs SV, Karunagaran D, et al. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol. 1994;14:1909-19.
13. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
14. Yarden Y, Sliwkowski MX. Untangling the erbB signaling network. Nat Rev Mol Cell Biol. 2001;2:127-37.
15. Kirschbaum MH, Yarden Y. The erbB/HER family of receptor tyrosine kinases: a potential target for chemoprevention of epithelial neoplasm. J Cell Biochem. 2000;34 (suppl):52-60.
16. Tang CK, Lippman ME. Hormones and signaling. In: O'Malley BW, ed. EGF family receptors and their ligands in human cancer. Burlington, Mass.: Academic Press; 1998:113-65.
17. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor CDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418-25.
18. Arteaga C. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7(suppl 4):31-9.
19. Carpenter G, Cohn S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216.
20. Watabe T, Yoshida K, Shindoh M, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer. 1998;77:128-37.
21. Collins VP. Gene amplification in human gliomas. Glia. 1995;15:289-96.
22. Reissmann PT, Koga H, Figlin RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 1999;125:61-70.
23. Peles E, Bacus SS, Koski RA, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992;69:205-16.
24. Peles E, Ben-Levy R, Tzahar E, et al. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 1993;12:961-71.
25. Colomer R, Shamon LA, Tsai MS, et al. Herceptin: from the bench to the clinic. Cancer Invest. 2001;19:49-56.
26. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3:237-52.
27. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791-808.
28. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
29. Torre EA, Salimbeni V, Fulco RA. The erbB-2 oncogene and chemotherapy: a mini-review. J Chemother. 1999;9:51-5.
30. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-65.
31. Siegel PM, Ryan ED, Cardiff RD, et al. Elevated expression of activated forms of neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implication for human breast cancer. EMBO J. 1999;18:2149-64.
32. Knowlden JM, Gee JM, Seery LT, et al. C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene. 1998;17:1949-57.
33. Naidu R, Yadav M, Nair S, et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385-90.
34. Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229-33.
35. Scrinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000;60:1483-87.
36. Kew TY, Bell JA, Pinder SE, et al. C-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163-70.
37. Vogt U, Bielawski K, Schlotter CM, et al. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene. 1998;223:375-80.
38. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
39. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-48.
40. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
41. Herceptin (trastuzumab) product labeling. South San Francisco, Calif.: Genentech; 2000.
42. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol. 2001;28(suppl 16):18-26.
43. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol. 2001;28(suppl 16):67-79.
44. Woodburn J, Kendrew J, Fennel M. ZD1839 ("Iressa") a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition [abstract]. Proc Am Assoc Cancer Res. 2000;41:402. Abstract 2552.
45. Fukuolka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol. 2002;21:298a. Abstract 1188.
46. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2) [abstract]. Proc Am Soc Clin Oncol. 2002;21:292a. Abstract 1166.
47. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small-cell lung cancer: review of literature results. Lung Cancer. 2001;34(suppl 4):95-101.
48. IRESSA (gefitinib) product labeling. Wilmington, Del.: AstraZeneca Pharmaceuticals; 2003.
49. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small-cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2001:310a. Abstract 1235.
50. Finkler N, Gordon A, Crozier M, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:208a. Abstract 831.
51. Senzer NN, Soulieres D, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol. 2001;20:2a. Abstract 6.
52. Etessami A, Bourhis J. Cetuximab. Drugs Future. 2000;25:895-99.
53. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy: the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Research Clinical Award Lecture. Clin Cancer Res. 2000;6:747-52.
54. Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin © + placebo (P) to C + anti-epidermal growth factor antibody (EGFR-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:226a.
55. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol. 2003:252. Abstract 1012.
56. Garrison M, Tolcher A, McCreery H. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001;20:72a. Abstract 283.
57. Shin D, Neumunaitis J, Zinner R. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001;20:82a. Abstract 324.
58. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother. 1998;47:183-90.
59. Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumor antigens. Immunology. 1998;93:192-9.